Colston KW, Hansen CM: Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer. 2002, 9: 45-59. 10.1677/erc.0.0090045.
Wu-Wong JR, Tian J, Goltzman D: Vitamin D analogs as therapeutic agents: a clinical study update. Curr Opin Investig Drugs. 2004, 5: 320-326.
Wu G, Fan RS, Li W, Ko TC, Brattain MG: Modulation of cell cycle control by vitamin D3 and its analogue, EB1089 in human breast cancer cells. Oncogene. 1997, 15: 1555-1563. 10.1038/sj.onc.1201329.
Jensen SS, Madsen MW, Lukas J, Binderup LT, Bartek J: Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol. 2001, 15: 1370-1380. 10.1210/me.15.8.1370.
Vink-van Wijngaarden T, Pols HA, Buurman CJ, van den Bemd GJ, Dorssers LC, Birkenhager JC, van Leeuwen JP: Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen. Cancer Res. 1994, 54: 5711-5717.
James SY, Mercer E, Brady M, Binderup L, Colston KW: EB1089 a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro. Br J Pharmacol. 1998, 125: 953-962. 10.1038/sj.bjp.0702103.
Koshizuka K, Koike M, Kubota T, Said J, Binderup L, Koeffler HP: Novel vitamin D3 analog (CB1093) when combined with paclitaxel and cisplatin inhibit growth of MCF-7 human breast cancer cells in vivo. Int J Oncol. 1998, 13: 421-428.
Koshizuka K, Koike M, Asou H, Cho SK, Stephen T, Rude RK, Binderup L, Uskokovic M, Koeffler HP: Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo. Breast Cancer Res Treat. 1999, 53: 113-120. 10.1023/A:1006123819675.
Sundaram S, Chaudhry M, Reardon D, Gupta M, Gewirtz DA: The vitamin D3 analog EB 1089 enhances the antiproliferative and apoptotic effects of adriamycin in MCF-7 breast tumor cells. Breast Cancer Res Treat. 2000, 63: 1-10. 10.1023/A:1006420708806.
Wang Q, Yang W, Uytingco MS, Christakos S, Wieder R: 1,25-Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death. Cancer Res. 2000, 60: 2040-2048.
Narvaez CJ, Welsh J: Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. J Biol Chem. 2001, 276: 9101-9107. 10.1074/jbc.M006876200.
Pirianov G, Colston KW: Interactions of vitamin D analogue CB1093 TNFalpha and ceramide on breast cancer cell apoptosis. Mol Cell Endocrinol. 2001, 172: 69-78. 10.1016/S0303-7207(00)00380-4.
Gulliford T, English J, Colston KW, Menday P, Moller S, Coombes RC: A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br J Cancer. 1998, 78: 6-13.
Fu GK, Lin D, Zhang MY, Bikle DD, Shackleton CH, Miller WL, Portale AA: Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol Endocrinol. 1997, 11: 1961-1970. 10.1210/me.11.13.1961.
Jones G, Strugnell SA, DeLuca HF: Current understanding of the molecular actions of vitamin D. Physiol Rev. 1998, 78: 1193-1231.
Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM, Hewison M: Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab. 2001, 86: 888-894. 10.1210/jc.86.2.888.
Segersten U, Correa P, Hewison M, Hellman P, Dralle H, Carling T, Akerstrom G, Westin G: 25-hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metab. 2002, 87: 2967-2972. 10.1210/jc.87.6.2967.
Howard GA, Turner RT, Sherrard DJ, Baylink DJ: Human bone cells in culture metabolize 25-hydroxyvitamin D3 to 1,25- dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3. J Biol Chem. 1981, 256: 7738-7740.
Cross HS, Peterlik M, Reddy GS, Schuster I: Vitamin D metabolism in human colon adenocarcinoma-derived Caco-2 cells: expression of 25-hydroxyvitamin D3-1alpha-hydroxylase activity and regulation of side-chain metabolism. J Steroid Biochem Mol Biol. 1997, 62: 21-28. 10.1016/S0960-0760(97)00020-4.
Bareis P, Bises G, Bischof MG, Cross HS, Peterlik M: 25-hydroxy-vitamin d metabolism in human colon cancer cells during tumor progression. Biochem Biophys Res Commun. 2001, 285: 1012-1017. 10.1006/bbrc.2001.5289.
Cross HS, Bareis P, Hofer H, Bischof MG, Bajna E, Kriwanek S, Bonner E, Peterlik M: 25-Hydroxyvitamin D(3)-1alpha-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids. 2001, 66: 287-292. 10.1016/S0039-128X(00)00153-7.
Tangpricha V, Flanagan JN, Whitlatch LW, Tseng CC, Chen TC, Holt PR, Lipkin MS, Holick MF: 25-hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue. Lancet. 2001, 357: 1673-1674. 10.1016/S0140-6736(00)04831-5.
Ogunkolade BW, Boucher BJ, Fairclough PD, Hitman GA, Dorudi S, Jenkins PJ, Bustin SA: Expression of 25-hydroxyvitamin D-1-alpha-hydroxylase mRNA in individuals with colorectal cancer. Lancet. 2002, 359: 1831-1832. 10.1016/S0140-6736(02)08680-4.
Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF: Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev. 1998, 7: 391-395.
Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF: The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Clin Cancer Res. 2000, 6: 901-908.
Hsu JY, Feldman D, McNeal JE, Peehl DM: Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res. 2001, 61: 2852-2856.
Correa P, Segersten U, Hellman P, Akerstrom G, Westin G: Increased 25-hydroxyvitamin D3 1alpha-hydroxylase and reduced 25-hydroxyvitamin D3 24-hydroxylase expression in parathyroid tumors – new prospects for treatment of hyperparathyroidism with vitamin d. J Clin Endocrinol Metab. 2002, 87: 5826-5829. 10.1210/jc.2002-021356.
Bland R, Walker EA, Hughes SV, Stewart PM, Hewison M: Constitutive expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in a transformed human proximal tubule cell line: evidence for direct regulation of vitamin D metabolism by calcium. Endocrinology. 1999, 140: 2027-2034. 10.1210/en.140.5.2027.
Zehnder D, Bland R, Walker EA, Bradwell AR, Howie AJ, Hewison M, Stewart PM: Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in the human kidney. J Am Soc Nephrol. 1999, 10: 2465-2473.
Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N, Blacher S, Verdin E, Foidart JM, Nusgens BV, Castronovo V: Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene. 2002, 21: 427-436. 10.1038/sj.onc.1205108.
Kahlen JP, Carlberg C: Functional characterization of a 1,25-dihydroxyvitamin D3 receptor binding site fouond in the rat atrial natriuretic factor promoter. Biochem Biophys Res Commun. 1996, 218: 882-886. 10.1006/bbrc.1996.0157.
Revillion F, Pawlowski V, Hornez L, Peyrat JP: Glyceraldehyde-3-phosphate dehydrogenase gene expression in human breast cancer. Eur J Cancer. 2000, 36: 1038-1042. 10.1016/S0959-8049(00)00051-4.
Segersten U, Holm PK, Binderup L, Akerstrom G, Hellman P, Westin G: Vitamin D3 polyunsaturated side-chain analogues (EB1089 GS1590) and the 20-epi-vitamin D3 analogue CB1393 suppress parathyroid hormone secretion and mRNA level in bovine parathyroid cells. J Steroid Biochem Mol Biol. 2004, 88: 289-294. 10.1016/j.jsbmb.2003.12.009.
Peehl DM, Seto E, Hsu JY, Feldman D: Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. J Urol. 2002, 168: 1583-1588. 10.1097/00005392-200210010-00089.
Shankar VN, Dilworth FJ, Makin HL, Schroeder NJ, Trafford DJ, Kissmeyer AM, Calverley MJ, Binderup E, Jones G: Metabolism of the vitamin D analog EB1089 by cultured human cells: redirection of hydroxylation site to distal carbons of the side-chain. Biochem Pharmacol. 1997, 53: 783-793. 10.1016/S0006-2952(96)00815-5.
Lin R, Nagai Y, Sladek R, Bastien Y, Ho J, Petrecca KS, Sotiropoulou G, Diamandis EP, Hudson TJ, White JH: Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol. 2002, 16: 1243-1256. 10.1210/me.16.6.1243.
Berger U, Wilson P, McClelland RA, Colston K, Haussler MR, Pike JW, Coombes RC: Immunocytochemical detection of 1,25-dihydroxyvitamin D3 receptor in breast cancer. Cancer Res. 1987, 47: 6793-6799.
Berger U, McClelland RA, Wilson P, Greene GL, Haussler MR, Pike JW, Colston K, Easton D, Coombes RC: Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Cancer Res. 1991, 51: 239-244.
Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, Kuo WL, Gray JW, Pinkel D: Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet. 2000, 25: 144-146. 10.1038/75985.
Miettinen S, Ahonen MH, Lou YR, Manninen T, Tuohimaa P, Syvala H, Ylikomi T: Role of 24-hydroxylase in vitamin D3 growth response of OVCAR-3 ovarian cancer cells. Int J Cancer. 2004, 108: 367-373. 10.1002/ijc.11520.
Whitlatch LW, Young MV, Schwartz GG, Flanagan JN, Burnstein KL, Lokeshwar BL, Rich ES, Holick MF, Chen TC: 25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J Steroid Biochem Mol Biol. 2002, 81: 135-140. 10.1016/S0960-0760(02)00053-5.
Huang DC, Papavasiliou V, Rhim JS, Horst RL, Kremer R: Targeted disruption of the 25-hydroxyvitamin D3 1alpha-hydroxylase gene in ras-transformed keratinocytes demonstrates that locally produced 1alpha,25-dihydroxyvitamin D3 suppresses growth and induces differentiation in an autocrine fashion. Mol Cancer Res. 2002, 1: 56-67.
Schuster I, Egger H, Nussbaumer P, Kroemer RT: Inhibitors of vitamin D hydroxylases: structure-activity relationships. J Cell Biochem. 2003, 88: 372-380. 10.1002/jcb.10365.
Ly LH, Zhao XY, Holloway L, Feldman D: Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology. 1999, 140: 2071-2076. 10.1210/en.140.5.2071.